ATE338557T1 - Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks - Google Patents
Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticksInfo
- Publication number
- ATE338557T1 ATE338557T1 AT02738138T AT02738138T ATE338557T1 AT E338557 T1 ATE338557 T1 AT E338557T1 AT 02738138 T AT02738138 T AT 02738138T AT 02738138 T AT02738138 T AT 02738138T AT E338557 T1 ATE338557 T1 AT E338557T1
- Authority
- AT
- Austria
- Prior art keywords
- tic
- cox2 inhibitors
- treat schizophrenia
- schizophrenia
- treat
- Prior art date
Links
- 229940111134 coxibs Drugs 0.000 title 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10129320A DE10129320A1 (de) | 2001-06-19 | 2001-06-19 | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
| US36490402P | 2002-03-14 | 2002-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE338557T1 true ATE338557T1 (de) | 2006-09-15 |
Family
ID=26009543
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02738138T ATE338557T1 (de) | 2001-06-19 | 2002-05-31 | Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks |
| AT05024864T ATE452642T1 (de) | 2001-06-19 | 2002-05-31 | Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05024864T ATE452642T1 (de) | 2001-06-19 | 2002-05-31 | Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040204469A1 (enExample) |
| EP (2) | EP1397145B1 (enExample) |
| JP (2) | JP4205577B2 (enExample) |
| AP (1) | AP1512A (enExample) |
| AT (2) | ATE338557T1 (enExample) |
| AU (1) | AU2002312967A1 (enExample) |
| CA (1) | CA2448025C (enExample) |
| CY (1) | CY1109949T1 (enExample) |
| DE (2) | DE60234873D1 (enExample) |
| DK (2) | DK1627639T3 (enExample) |
| EA (1) | EA009780B1 (enExample) |
| ES (2) | ES2336682T3 (enExample) |
| OA (1) | OA12627A (enExample) |
| PT (2) | PT1397145E (enExample) |
| SI (1) | SI1627639T1 (enExample) |
| WO (1) | WO2002102297A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR032641A1 (es) * | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US8703772B2 (en) | 2001-09-25 | 2014-04-22 | Otsuka Pharmaceutical Co., Ltd. | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| MXPA05005611A (es) * | 2002-11-26 | 2005-07-27 | Alexza Pharmaceuticals Inc | Uso de loxapina y amoxapina para la fabricacion de un medicamento para el tratamiento del dolor. |
| US20040204411A1 (en) * | 2002-12-17 | 2004-10-14 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
| JP2007502856A (ja) * | 2003-05-16 | 2007-02-15 | ファイザー・プロダクツ・インク | 精神病性障害および抑うつ性障害の治療 |
| CA2526478A1 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same |
| WO2005020976A2 (en) * | 2003-08-27 | 2005-03-10 | Eli Lilly And Company | Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors |
| WO2005048999A2 (en) * | 2003-11-19 | 2005-06-02 | Glaxo Group Limited | Use of cyclooxygenase-2 inhibitors for the treatment of depressive disorders |
| WO2005049034A2 (en) * | 2003-11-19 | 2005-06-02 | Glaxo Group Limited | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders |
| US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
| JP2007526328A (ja) * | 2004-03-02 | 2007-09-13 | ファルマシア コーポレーション | 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物 |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| AU2004322756B2 (en) | 2004-08-12 | 2011-04-14 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
| US20070281927A1 (en) * | 2006-06-06 | 2007-12-06 | Shanthakumar Tyavanagimatt | Anti-inflammatory and analgesic compositions and related methods |
| GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
| ES2594867T3 (es) | 2007-03-09 | 2016-12-23 | Alexza Pharmaceuticals, Inc. | Unidad de calentamiento para usar en un dispositivo de administración de fármaco |
| JP5144104B2 (ja) | 2007-04-09 | 2013-02-13 | ユニ・チャーム株式会社 | 伸縮性複合シート及びそれを用いた使い捨て着用物品 |
| EP2485744A4 (en) * | 2009-10-09 | 2014-01-22 | Prothera Inc | COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED |
| EP2340819A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising venlafaxine and celecoxib in the treatment of pain |
| EP2340818A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of venlafaxine and celecoxib |
| CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
| AU2018379992B2 (en) | 2017-12-05 | 2022-07-21 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| MX2020007997A (es) | 2018-02-02 | 2020-12-03 | Alexza Pharmaceuticals Inc | Dispositivo electrico de aerosol de condensacion. |
| CA3142355A1 (en) | 2019-06-04 | 2020-12-10 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4564614A (en) * | 1984-10-11 | 1986-01-14 | Pfizer Inc. | Antiinflammatory methods |
| WO1999025353A1 (en) * | 1997-11-13 | 1999-05-27 | Merck Sharp & Dohme Limited | Therapeutic uses of triazolo-pyridazine derivatives |
| ATE305788T1 (de) * | 1999-07-01 | 2005-10-15 | Pharmacia & Upjohn Co Llc | (s,s)-reboxetin zur behandlung von inkontinenz |
| EP1142889A1 (en) * | 2000-04-03 | 2001-10-10 | Pfizer Products Inc. | Pyrazole derivatives as anti-inflammatory/analgesic agents |
| US6306842B1 (en) * | 2000-06-02 | 2001-10-23 | Medinox, Inc. | Protected forms of a combination of pharmacologically active agents and uses therefor |
-
2002
- 2002-05-31 US US10/480,600 patent/US20040204469A1/en not_active Abandoned
- 2002-05-31 AT AT02738138T patent/ATE338557T1/de active
- 2002-05-31 WO PCT/EP2002/006013 patent/WO2002102297A2/en not_active Ceased
- 2002-05-31 OA OA1200300328A patent/OA12627A/en unknown
- 2002-05-31 AT AT05024864T patent/ATE452642T1/de active
- 2002-05-31 AU AU2002312967A patent/AU2002312967A1/en not_active Abandoned
- 2002-05-31 EA EA200301291A patent/EA009780B1/ru not_active IP Right Cessation
- 2002-05-31 EP EP02738138A patent/EP1397145B1/en not_active Expired - Lifetime
- 2002-05-31 ES ES05024864T patent/ES2336682T3/es not_active Expired - Lifetime
- 2002-05-31 JP JP2003504886A patent/JP4205577B2/ja not_active Expired - Fee Related
- 2002-05-31 DE DE60234873T patent/DE60234873D1/de not_active Expired - Lifetime
- 2002-05-31 AP APAP/P/2003/002934A patent/AP1512A/en active
- 2002-05-31 EP EP05024864A patent/EP1627639B1/en not_active Expired - Lifetime
- 2002-05-31 PT PT02738138T patent/PT1397145E/pt unknown
- 2002-05-31 DK DK05024864.0T patent/DK1627639T3/da active
- 2002-05-31 ES ES02738138T patent/ES2271269T3/es not_active Expired - Lifetime
- 2002-05-31 SI SI200230890T patent/SI1627639T1/sl unknown
- 2002-05-31 DK DK02738138T patent/DK1397145T3/da active
- 2002-05-31 PT PT05024864T patent/PT1627639E/pt unknown
- 2002-05-31 CA CA2448025A patent/CA2448025C/en not_active Expired - Fee Related
- 2002-05-31 DE DE60214542T patent/DE60214542T2/de not_active Expired - Lifetime
-
2008
- 2008-07-22 JP JP2008188890A patent/JP4824727B2/ja not_active Expired - Fee Related
-
2010
- 2010-03-22 CY CY20101100270T patent/CY1109949T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002102297A2 (en) | 2002-12-27 |
| ES2336682T3 (es) | 2010-04-15 |
| JP2004534066A (ja) | 2004-11-11 |
| EA009780B1 (ru) | 2008-04-28 |
| SI1627639T1 (sl) | 2010-04-30 |
| CY1109949T1 (el) | 2014-09-10 |
| ES2271269T3 (es) | 2007-04-16 |
| JP4205577B2 (ja) | 2009-01-07 |
| JP2008297308A (ja) | 2008-12-11 |
| EP1627639B1 (en) | 2009-12-23 |
| ATE452642T1 (de) | 2010-01-15 |
| OA12627A (en) | 2006-06-13 |
| DE60234873D1 (de) | 2010-02-04 |
| EP1627639A3 (en) | 2006-09-27 |
| WO2002102297A3 (en) | 2003-05-01 |
| US20040204469A1 (en) | 2004-10-14 |
| EA200301291A1 (ru) | 2004-06-24 |
| DK1627639T3 (da) | 2010-04-26 |
| CA2448025C (en) | 2011-07-05 |
| DK1397145T3 (da) | 2007-01-02 |
| PT1397145E (pt) | 2006-10-31 |
| DE60214542T2 (de) | 2006-12-21 |
| CA2448025A1 (en) | 2002-12-27 |
| EP1397145A2 (en) | 2004-03-17 |
| AP2003002934A0 (en) | 2003-12-31 |
| EP1397145B1 (en) | 2006-09-06 |
| AP1512A (en) | 2005-12-15 |
| JP4824727B2 (ja) | 2011-11-30 |
| DE60214542D1 (de) | 2006-10-19 |
| EP1627639A2 (en) | 2006-02-22 |
| PT1627639E (pt) | 2010-03-01 |
| AU2002312967A1 (en) | 2003-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60214542D1 (de) | Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks | |
| ATE473753T1 (de) | Verwendung von botulinum toxin zur behandlung von post-operative schmerzen | |
| EP1438054A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF FLAVIVIRES AND PESTIVERS WITH 4'-MODIFIED NUCLEOSIDE | |
| DE60223694D1 (de) | Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums | |
| DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| ATE410421T1 (de) | P38 inhibitor und anwendungsverfahren dafür | |
| ATE419856T1 (de) | Verwendung von rimexolon zur behandlung von augentrockenheit | |
| EE200300459A (et) | Uued spirotritsüklilised derivaadid ja nende kasutamine fosfodiesteraas-7 inhibiitoritena | |
| ATE307597T1 (de) | Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c | |
| DE60140377D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| ATE365042T1 (de) | Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen | |
| ATE353218T1 (de) | Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis | |
| DE60221798D1 (de) | Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen | |
| ATE395075T1 (de) | Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose | |
| DE60216495D1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
| DE60226855D1 (de) | Verwendung von (z)-2-cyano-3-hydroxy-but-2-ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose | |
| ATE290786T1 (de) | Fungizide zusammensetzung und verwendung dieser zusammensetzung zur bekämpfung von pflanzenkrankheiten | |
| PL357674A1 (pl) | Kompozycje i sposoby leczenia zaburzeń związanychz hiperlipidemią | |
| DE60322898D1 (de) | Verwendung von isoflavonen zur förderung des schlankheitseffekts | |
| ATE304854T1 (de) | Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne | |
| DE50114605D1 (de) | No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| ATE380558T1 (de) | Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten | |
| DE69835006D1 (de) | Inhibitoren des algenwachstums und ihre verwendung | |
| DE60233740D1 (de) | Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit | |
| ATE317261T1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1397145 Country of ref document: EP |